Nexo Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
Overview
A biotech developing small molecule drugs for undruggable cancer targets using a proprietary chemical proteomics platform.
Oncology
Technology Platform
A proprietary chemical proteomics platform designed to discover small molecules that target traditionally undruggable proteins, such as transcription factors, in cancer.
Funding History
1Total raised:$60M
Series A$60M
Opportunities
Successfully drugging a validated but elusive cancer target could yield a blockbuster therapy with a strong intellectual property position.
Risk Factors
High technical risk associated with the novel platform and the inherent difficulty of validating and drugging unprecedented targets.
Competitive Landscape
Competes in the crowded 'undruggable target' space against companies like Revolution Medicines and Foghorn Therapeutics, differentiated by its specific chemical proteomics focus.